GlassScriptPhysician profile
Samuel Molica
NPI 1750792511
$6,976.24
in general payments reported to CMS, 2019-2025
29 companies · $484 in 2025
The $484 reported for 2025 was more than what a typical Surgery provider received nationally (typical 2025 total: $281).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $392 · 2022: $454 · 2023: $424 · 2024: $5,222 · 2025: $484.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Education: $4,000 · Food and Beverage: $1,418 · Travel and Lodging: $713.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Education | $4,000.00 |
| Food and Beverage | $1,417.65 |
| Travel and Lodging | $712.56 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Intuitive Surgical, INC. | $5,139.58 | 2024-2025 | |
| Baxter Healthcare | $640.57 | 2021-2025 | Perclot, Floseal, Tisseel |
| Acelrx Pharmaceuticals, INC. | $195.57 | 2021 | |
| Novo Nordisk INC | $110.17 | 2023-2024 | Wegovy |
| Smith+Nephew, INC. | $91.46 | 2023-2025 | Collagenase Santyl |
| Myriad Genetic Laboratories, INC. | $79.29 | 2023 | Myrisk |
| Boston Scientific Corporation | $78.20 | 2022 | |
| Ethicon US, LLC | $60.36 | 2021-2024 | Linx Reflux Management System |
| Tela Bio, INC. | $58.12 | 2021-2024 | Ovitex 2s |
| Urovant Sciences INC | $55.80 | 2022 | |
| Davol INC. | $46.18 | 2021-2023 | Phasix Mesh |
| Takeda Pharmaceuticals U.S.A., INC. | $45.30 | 2025 | Gattex, Eohilia |
| Madrigal Pharmaceuticals | $40.13 | 2025 | Rezdiffra |
| Pharmacosmos Therapeutics INC. | $36.58 | 2022-2023 | Monoferric |
| Regeneron Healthcare Solutions, INC. | $32.66 | 2025 | Libtayo |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Medtronic, INC. | $26.54 | 2025 | Maxtack |
| Janssen Pharmaceuticals, INC | $23.35 | 2021 | |
| Merck Sharp & Dohme LLC | $22.53 | 2023 | Gardasil 9, Vaxelis, Rotateq |
| Phathom Pharmaceuticals, INC. | $21.03 | 2024 | Voquezna |
| Braintree Laboratories, INC. | $20.79 | 2022 | |
| Integra Lifesciences Corporation | $19.70 | 2022 | |
| Kerecis Limited | $19.42 | 2022 | |
| Musculoskeletal Transplant Foundation INC. | $18.41 | 2022 | |
| Convatec INC. | $18.31 | 2022 | |
| Kci USA, INC. | $18.15 | 2023 | Activ.A.C. Ion Progress, Prevena, V.A.C. Dermatac |
| Glaxosmithkline, LLC. | $16.09 | 2023 | Arexvy |
| Bioventus LLC | $14.24 | 2025 | Xcell |
| Vertex Pharmaceuticals Incorporated | $14.00 | 2025 | |
| Pfizer INC. | $13.71 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Samuel Molica listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.